U.S. Markets closed

Rafarma Pharmaceuticals, Inc. (RAFA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3900+0.0375 (+10.64%)
At close: 12:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3525
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3600 - 0.4400
52 Week Range0.2410 - 1.4700
Avg. Volume26,087
Market Cap51.821M
Beta (5Y Monthly)-0.18
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rafarma Pharmaceuticals strengthens its position in Central Asia

    Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production. Over the next three ye

  • GlobeNewswire

    Rafarma’s Slavich Noya Technology Division Expands Printing Production

    Nicosia, Cyprus, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) Slavich Noya Technology, part of the Rafarma Pharmaceuticals group of companies, is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST (, one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated boa

  • GlobeNewswire

    RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research

    Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radi